Oppenheimer & Co. Inc. Buys 1,078 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Oppenheimer & Co. Inc. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,792 shares of the biopharmaceutical company’s stock after purchasing an additional 1,078 shares during the period. Oppenheimer & Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $19,136,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Board of the Pension Protection Fund purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. Caitlin John LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $38,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,774 shares of company stock valued at $2,942,738 in the last three months. 7.02% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on REGN shares. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Evercore lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Finally, JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $825.68.

Regeneron Pharmaceuticals Stock Up 3.0%

Shares of REGN opened at $707.06 on Friday. The firm has a market cap of $74.75 billion, a P/E ratio of 17.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company’s 50-day moving average price is $756.81 and its 200 day moving average price is $735.17. The company has a current ratio of 4.15, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm earned $8.22 EPS. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat expectations: Regeneron reported Q1 revenue up 19% to ~$3.6B and non‑GAAP EPS of $9.47, beating estimates, driven by strong Dupixent demand and Libtayo. This underpins near‑term top‑line momentum. Reuters: Regeneron beats quarterly results
• Positive Sentiment: $3 billion buyback announced and dividend declared: Management authorized up to $3B in share repurchases and declared a $0.94 quarterly dividend, both shareholder-friendly actions that support EPS and investor returns. Seeking Alpha: buyback mention
• Positive Sentiment: Pipeline progress could drive medium‑term upside: Management reported C5 program milestones (pivotal PNH enrollment complete, positive Phase III for cemdisiran in gMG) and potential multi‑indication launches as soon as late‑2026 — important optionality beyond core franchises. Yahoo: C5 milestones & pipeline
• Neutral Sentiment: Analyst target adjustments but mixed ratings: Several shops trimmed price targets (RBC to $762, Wells Fargo to $800, Truist to $796, Barclays to $917) while many retained buy/overweight stances — suggests analysts are tuning models post‑earnings but still see upside. TickerReport/Benzinga: price target moves
• Neutral Sentiment: Analysts trimmed near‑term forecasts: Firms modestly cut forecasts after Q1, reflecting product mix and competitive assumptions; important to watch updated guidance and modeling revisions. Benzinga: analysts cut forecasts
• Negative Sentiment: Market punished stock on Eylea weakness and competitive risk: U.S. high‑dose Eylea sales underperformed expectations and competition in the retina market is intensifying — this drove the immediate post‑earnings weakness despite the beat. Yahoo: Eylea sales miss
• Negative Sentiment: Q1 net income decline: GAAP net income fell ~10% to $727M year‑over‑year, reflecting some one‑time items and mix; investors sensitive to margin and profitability trends may see this as a near‑term headwind. Pharma‑Technology: net income falls

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.